Overview

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.

Phase:

Phase 1

Details

Lead Sponsor:

Facet Biotech

Treatments:

Elotuzumab